Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of metastatic colorectal adenocarcinoma that is not amenable to curative therapy.~* Patient must have at least one unidimensionally measurable lesion.~* Prior radiation therapy to less than 25% of bone marrow. Radiation must be completed at least 4 weeks prior to study enrollment.~* Performance status 0 to 2~* Patient must have received 1 prior course of chemotherapy (Folfox regimen) for metastatic disease~Exclusion Criteria:~* Treatment with any drug within the last 30 days that has not received regulatory approval.~* Serious systemic disorder (cardiac or pulmonary disease, active infection)~* Documented brain metastases not amenable to surgery or unstable after radiation~* Inability or unwillingness to take folic acid or Vitamin B12 supplementation.~* Presence of fluid retention that can not be controlled by drainage.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed + Irinotecan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).